Understanding efflux in Gram-negative bacteria: Opportunities for drug discovery

Expert Opinion on Drug Discovery

Volumn 7, Issue 7, 2012, Pages 633-642

  Schweizer, Herbert P ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

Drug discovery; Drug resistance; Efflux; Gram negative bacteria; Pump inhibition

Indexed keywords

1 (1 NAPHTHYLMETHYL)PIPERAZINE; ALKYLAMINOQUINAZOLINE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CBR 4830; CHIR 090; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; D 139001; EFFLUX PUMP INHIBITOR; INDOLE DERIVATIVE; KETOLIDE; LIPOPOLYSACCHARIDE; MACROLIDE; MP 601205; NALIDIXIC ACID; NORFLOXACIN; NOVOBIOCIN; OXAZOLIDINONE DERIVATIVE; PHENOTHIAZINE DERIVATIVE; PHENYLALANINE ARGINYL BETA NAPHTYLAMIDE; PHENYLALANYLARGININE 2 NAPHTHYLAMIDE; PORIN; RIFAMPICIN; RIFAMYCIN; SPARFLOXACIN; TETRACYCLINE; TRIMETHOPRIM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL CELL; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM EFFLUX PUMP; BACTERIUM ISOLATE; BIOFILM; CELL MEMBRANE PERMEABILITY; DRUG DIFFUSION; DRUG PENETRATION; DRUG POTENTIATION; DRUG STRUCTURE; ESCHERICHIA COLI; GENE SILENCING; GRAM NEGATIVE BACTERIUM; HUMAN; KLEBSIELLA PNEUMONIAE; LUNG INFECTION; MULTIDRUG RESISTANCE; NONHUMAN; OUTER MEMBRANE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; RESISTANCE NODULATION CELL DIVISION SUPERFAMILY; REVIEW; SALMONELLA ENTERICA;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BIOFILMS; CELL MEMBRANE PERMEABILITY; CELL WALL; DRUG DISCOVERY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; HUMANS; LIPOPOLYSACCHARIDES; MEMBRANE TRANSPORT PROTEINS; PORINS; RNA INTERFERENCE;

EID: 84862850350     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2012.688949     Document Type: Review

References (100)

1. Walsh C. Antibiotic Resistance. American Society for Microbiology Press; Washington, D.C: 2003
2. Silver LL. Challenges of antibacterial discovery. Clin Microbiol Rev 2011;24(1):71-109
3. Lewis K. Multidrug tolerance of biofilms and persister cells. Curr Top Microbiol Immunol 2008;322:107-31
4. Davies JC, Bilton D. Bugs, biofilms, and resistance in cystic fibrosis. Respir Care 2009;54(5):628-40
5. Hoiby N, Bjarnsholt T, Givskov M, et al. Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents 2010;35(4):322-32
6. Haussler S, Rohde M, Steinmetz I. Highly resistant Burkholderia pseudomallei small colony variants isolated in vitro and in experimental melioidosis. Med Microbiol Immunol 1999;188:91-7
7. Fetar H, Gilmour C, Klinoski R, et al. mexEF-oprN multidrug efflux operon of Pseudomonas aeruginosa: regulation by the MexT activator in response to nitrosative stress and chloramphenicol. Antimicrob Agents Chemother 2011;55(2):508-14
8. Fraud S, Poole K. Oxidative stress induction of the MexXY multidrug efflux genes and promotion of aminoglycoside resistance development in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2011;55(3):1068-74
9. Poole K. Pseudomonas aeruginosa: resistance to the max. Front Microbiol 2011;2:65
10. Piddock LJ. Multidrug-resistance efflux pumps - not just for resistance. Nat Rev Microbiol 2006;4:629-36 (Pubitemid 44317025)
11. Piddock LJ. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin Microbiol Rev 2006;19:382-402
12. Lomovskaya O, Zgurskaya HI, Totrov M, Watkins WJ. Waltzing transporters and 'the dance macabre' between humans and bacteria. Nat Rev Drug Discov 2007;6(1):56-65 (Pubitemid 46020286)
13. Li XZ, Nikaido H. Efflux-mediated drug resistance in bacteria: an update. Drugs 2009;69(12):1555-623
14. Nikaido H, Pages JM. Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria. FEMS Microbiol Rev 2012;36(2):340-63
15. Balganesh M, Dinesh N, Sharma S, et al. Efflux Pumps of Mycobacterium tuberculosis play a significant role in anti-tuberculosis activity of potential drug candidates. Antimicrob Agents Chemother 2012;56(5):2643-51
16. Li X, Zolli-Juran M, Cechetto JD, et al. Multicopy suppressors for novel antibacterial compounds reveal targets and drug efflux susceptibility. Chem Biol 2004;11(10):1423-30 (Pubitemid 39351379)
17. Caughlan RE, Jones AK, Delucia AM, et al. Mechanisms decreasing in vitro susceptibility to the LpxC inhibitor CHIR-090 in the gram-negative pathogen Pseudomonas aeruginosa. Antimicrob Agents Chemother 2012;56(1):17-27
18. Poole K. Uninhibited antibiotic target discovery via chemical genetics. Nat Biotechnol 2004;22:1528-9 (Pubitemid 40039454)
19. Pages JM, James CE, Winterhalter M. The porin and the permeating antibiotic: a selective diffusion barrier in Gram-negative bacteria. Nat Rev Microbiol 2008;6(12):893-903
20. Hancock REW. Resistance mechanisms in Pseudomonas aeruginosa and other non-fermentative bacteria. Clin Infect Dis 1998;27(Suppl 1):S93-9 (Pubitemid 28375865)
21. Raetz CRH, Whitfield C. Lipopolysaccharide endotoxins. Annu Rev Biochem 2002;71:635-700
22. Raetz CR, Reynolds CM, Trent MS, Bishop RE. Lipid A modification systems in gram-negative bacteria. Annu Rev Biochem 2007;76:295-329
23. Sampson BA, Misra R, Benson SA. Identification and characterization of a new gene of Escherichia coli K-12 involved in outer membrane permeability. Genetics1989;122(3):491-501
24. Silhavy TJ, Kahne D, Walker S. The bacterial cell envelope. Cold Spring Harb Perspect Biol 2010;2(5):a000414
25. Novem V, Shui G, Wang D, et al. Structural and biological diversity of lipopolysaccharides from Burkholderia pseudomallei and Burkholderia thailandensis. Clin Vaccine Immunol 2009;16(10):1420-8
26. Hancock RE. Aminoglycoside uptake and mode of action-with special reference to streptomycin and gentamicin. I. Antagonists and mutants. J Antimicrob Chemother 1981;8(4):249-76 (Pubitemid 12201569)
27. Godfrey AJ, Shahrabadi MS, Bryan LE. Distribution of porin and lipopolysaccharide antigens on a Pseudomonas aeruginosa permeability mutant. Antimicrob Agents Chemother 1986;30(5):802-5 (Pubitemid 17187720)
28. Clements JM, Coignard F, Johnson I, et al. Antibacterial activities and characterization of novel inhibitors of LpxC. Antimicrob Agents Chemother 2002;46(6):1793-9 (Pubitemid 34535199)
29. Kline T, Andersen NH, Harwood EA, et al. Potent, novel in vitro inhibitors of the Pseudomonas aeruginosa deacetylase LpxC. J Med Chem 2002;45(14):3112-29 (Pubitemid 34721533)
30. Mdluli KE, Witte PR, Kline T, et al. Molecular validation of LpxC as an antibacterial drug target in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006;50(6):2178-84 (Pubitemid 43807540)
31. Barb AW, Zhou P. Mechanism and inhibition of LpxC: an essential zinc-dependent deacetylase of bacterial lipid A synthesis. Curr Pharm Biotechnol 2008;9(1):9-15 (Pubitemid 351266965)
32. Langsdorf EF, Malikzay A, Lamarr WA, et al. Screening for antibacterial inhibitors of the UDP-3-O-(R-3- hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) using a high-throughput mass spectrometry assay. J Biomol Screen 2010;15(1):52-61
33. Lee CJ, Liang X, Chen X, et al. Species-specific and inhibitor-dependent conformations of LpxC: implications for antibiotic design. Chem Biol 2011;18(1):38-47
34. Brown MF, Reilly U, Abramite JA, et al. Potent inhibitors of LpxC for the treatment of gram-negative infections. J Med Chem 2012;55(2):914-23
35. Srinivas N, Jetter P, Ueberbacher BJ, et al. Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa. Science 2010;327(5968):1010-13
36. Kumar A, Schweizer HP. Bacterial resistance to antibiotics: active efflux and reduced uptake. Adv Drug Deliv Rev 2005;57:1486-513
37. Tal N, Schuldiner S. A coordinated network of transporters with overlapping specificities provides a robust survival strategy. Proc Natl Acad Sci USA 2009;106(22):9051-6
38. Cloeckaert A, Baucheron S, Chaslus-Dancla E. Nonenzymatic chloramphenicol resistance mediated by IncC plasmid R55 is encoded by a floR gene variant. Antimicrob Agents Chemother 2001;45(8):2381-2 (Pubitemid 32664484)
39. Poole K, Srikumar R. Multidrug efflux in Pseudomonas aeruginosa: components, mechanisms and clinical significance. Curr Topics Med Chem 2001;1:59-71
40. Chopra I. New developments in tetracycline antibiotics: glycylcyclines and tetracycline efflux pump inhibitors. Drug Resist Updat 2002;5(3-4):119-25 (Pubitemid 35033803)
41. Butaye P, Cloeckaert A, Schwarz S. Mobile genes coding for efflux-mediated antimicrobial resistance in Gram-positive and Gram-negative bacteria. Int J Antimicrob Agents 2003;22:205-10 (Pubitemid 37103201)
42. Schwarz S, Kehrenberg C, Doublet B, Cloeckaert A. Molecular basis of bacterial resistance to chloramphenicol and florfenicol. FEMS Microbiol Rev 2004;28(5):519-42 (Pubitemid 39469918)
43. Hooper DC. Efflux pumps and nosocomial antibiotic resistance: a primer for hospital epidemiologists. Clin Infect Dis 2005;40(12):1811-17 (Pubitemid 40799953)
44. Rothstein DM, McGlynn M, Bernan V, et al. Detection of tetracyclines and efflux pump inhibitors. Antimicrob Agents Chemother 1993;37(8):1624-9 (Pubitemid 23226373)
45. Levy SB. The challenge of antibiotic resistance. Sci Am 1998;278(3):46-53
46. Nelson ML, Levy SB. Reversal of tetracycline resistance mediated by different bacterial tetracycline resistance determinants by an inhibitor of the Tet (B) antiport protein. Antimicrob Agents Chemother 1999;43:1719-24 (Pubitemid 29331254)
47. Nelson ML. Attacking the superbugs. Drug Disc World 2002;Spring:77-82
48. Lee A, Mao W, Warren MS, et al. Interplay between efflux pumps may provide either additive or multiplicative effects on drug resistance. J Bacteriol 2000;182:3142-50 (Pubitemid 30326929)
49. Lomovskaya O, Watkins W. Inhibition of efflux pumps as a novel approach to combat drug resistance in bacteria. J Mol Microbiol Biotechnol 2001;3:225-36 (Pubitemid 32257908)
50. Poole K. Efflux-mediated antimicrobial resistance. J Antimicrob Chemother 2005;56:20-51 (Pubitemid 41418335)
51. Deininger KN, Horikawa A, Kitko RD, et al. A requirement of TolC and MDR efflux pumps for acid adaptation and GadAB induction in Escherichia coli. PLoS One 2011;6(4):e18960
52. Kvist M, Hancock V, Klemm P. Inactivation of efflux pumps abolishes bacterial biofilm formation. Appl Environ Microbiol 2008;74(23):7376-82 (Pubitemid 352773583)
53. Hirakata Y, Kondo A, Hoshino K, et al. Efflux pump inhibitors reduce the invasiveness of Pseudomonas aeruginosa. Int J Antimicrob Agents 2009;34(4):343-6
54. Ferhat M, Atlan D, Vianney A, et al. The TolC protein of Legionella pneumophila plays a major role in multi-drug resistance and the early steps of host invasion. PLoS One 2009;4(11):e7732
55. Buckley AM, Webber MA, Cooles S, et al. The AcrAB-TolC efflux system of Salmonella enterica serovar Typhimurium plays a role in pathogenesis. Cell Microbiol 2006;8(5):847-56
56. Gil H, Platz GJ, Forestal CA, et al. Deletion of TolC orthologs in Francisella tularensis identifies roles in multidrug resistance and virulence. Proc Natl Acad Sci USA 2006;103(34):12897-902
57. Reddy JD, Reddy SL, Hopkins DL, Gabriel DW. TolC is required for pathogenicity of Xylella fastidiosa in Vitis vinifera grapevines. Mol Plant Microbe Interact 2007;20(4):403-10 (Pubitemid 46449398)
58. Koronakis V, Sharff A, Koronakis E, et al. Crystal structure of the bacterial membrane protein TolC central to multidrug efflux and protein export. Nature 2000;405:914-19 (Pubitemid 30435040)
59. Murakami S, Nakashima R, Yamashita E, Yamaguchi A. Crystal structure of bacterial multidrug efflux transporter AcrB. Nature 2002;419:587-93
60. Yu EW, McDermott G, Zgurskaya HI, et al. Structural basis of multiple drug-binding capacity of the AcrB multidrug efflux pump. Science 2003;300(5621):976-80 (Pubitemid 36548884)
61. Akama H, Matsuura T, Kashiwagi S, et al. Crystal structure of the membrane fusion protein, MexA, of the multidrug transporter in Pseudomonas aeruginosa. J Biol Chem 2004;279(25):25939-42 (Pubitemid 38798733)
62. Lambert O, Benabdelhak H, Chami M, et al. Trimeric structure of OprN and OprM efflux proteins from Pseudomonas aeruginosa, by 2D electron crystallography. J Struct Biol 2005;150(1):50-7 (Pubitemid 40395301)
63. Murakami S, Nakashima R, Yamashita E, et al. Crystal structures of a multidrug transporter reveal a functionally rotating mechanism. Nature 2006;443(7108):173-9 (Pubitemid 44387601)
64. Seeger MA, Schiefner A, Eicher T, et al. Structural asymmetry of AcrB trimer suggests a peristaltic pump mechanism. Science 2006;313(5791):1295-8 (Pubitemid 44330954)
65. Sennhauser G, Amstutz P, Briand C, et al. Drug export pathway of multidrug exporter AcrB revealed by DARPin inhibitors. PLoS Biol 2007;5(1):e7
66. Sennhauser G, Bukowska MA, Briand C, Grutter MG. Crystal structure of the multidrug exporter MexB from Pseudomonas aeruginosa. J Mol Biol 2009;389(1):134-45
67. Lynch AS. Efflux systems in bacterial pathogens: an opportunity for therapeutic intervention? An industry view. Biochem Pharmacol 2006;71(7):949-56
68. Mahamoud A, Chevalier J, Alibert-Franco S, et al. Antibiotic efflux pumps in Gram-negative bacteria: the inhibitor response strategy. J Antimicrob Chemother 2007;59(6):1223-9 (Pubitemid 47073340)
69. Stavri M, Piddock LJ, Gibbons S. Bacterial efflux pump inhibitors from natural sources. J Antimicrob Chemother 2007;59(6):1247-60 (Pubitemid 47073343)
70. Vergidis PI, Falagas ME. Multidrug-resistant Gram-negative bacterial infections: the emerging threat and potential novel treatment options. Curr Opin Investig Drugs 2008;9(2):176-83 (Pubitemid 351206376)
71. Martins M, Dastidar SG, Fanning S, et al. Potential role of non-antibiotics (helper compounds) in the treatment of multidrug-resistant Gram-negative infections: mechanisms for their direct and indirect activities. Int J Antimicrob Agents 2008;31(3):198-208
72. Kamicker BJ, Sweeney MT, Kaczmarek F, et al. Bacterial efflux pump inhibitors. Methods Mol Med 2008;142:187-204
73. Vila J, Martinez JL. Clinical impact of the over-expression of efflux pump in nonfermentative Gram-negative bacilli, development of efflux pump inhibitors. Curr Drug Targets 2008;9(9):797-807
74. Zechini B, Versace I. Inhibitors of multidrug resistant efflux systems in bacteria. Recent Patents Anti Infect Drug Discov 2009;4(1):37-50
75. Piddock LJ, Garvey MI, Rahman MM, Gibbons S. Natural and synthetic compounds such as trimethoprim behave as inhibitors of efflux in Gram-negative bacteria. J Antimicrob Chemother 2010;65(6):1215-23
76. Tegos GP, Haynes M, Strouse JJ, et al. Microbial efflux pump inhibition: tactics and strategies. Curr Pharm Des 2011;17(13):1291-302
77. Pages JM, Amaral L, Fanning S. An original deal for new molecule: reversal of efflux pump activity, a rational strategy to combat gram-negative resistant bacteria. Curr Med Chem 2011;18(19):2969-80
78. Lomovskaya O, Warren MS, Lee A, et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother 2001;45:105-16 (Pubitemid 32039101)
79. Matsumoto Y, Hayama K, Sakakihara S, et al. Evaluation of multidrug efflux pump inhibitors by a new method using microfluidic channels. PLoS One 2011;6(4):e18547
80. Renau TE, Leger R, Flamme EM, et al. Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin. J Med Chem 1999;42:4928-31
81. Hasdemir UO, Chevalier J, Nordmann P, Pages JM. Detection and prevalence of active drug efflux mechanism in various multidrug-resistant Klebsiella pneumoniae strains from Turkey. J Clin Microbiol 2004;42(6):2701-6 (Pubitemid 38747524)
82. Mazzariol A, Tokue Y, Kanegawa TM, et al. High-level fluoroquinolone- resistant clinical isolates of Escherichia coli overproduce multidrug efflux protein AcrA. Antimicrob Agents Chemother 2000;44(12):3441-3 (Pubitemid 33009509)
83. Baucheron S, Imberechts H, Chaslus-Dancla E, Cloeckaert A. The AcrB multidrug transporter plays a major role in high-level fluoroquinolone resistance in Salmonella enterica serovar typhimurium phage type DT204. Microb Drug Resist 2002;8(4):281-9 (Pubitemid 36043694)
84. Mallea M, Chevalier J, Eyraud A, Pages JM. Inhibitors of antibiotic efflux pump in resistant Enterobacter aerogenes strains. Biochem Biophys Res Commun 2002;293(5):1370-3 (Pubitemid 34681027)
85. Mamelli L, Amoros JP, Pages JM, Bolla JM. A phenylalanine-arginine etanaphthylamide sensitive multidrug efflux pump involved in intrinsic and acquired resistance of Campylobacter to macrolides. Int J Antimicrob Agents 2003;22:237-41 (Pubitemid 37103206)
86. Cortez-Cordova J, Kumar A. Activity of the efflux pump inhibitor phenylalanine-arginine betanaphthylamide against the AdeFGH pump of Acinetobacter baumannii. Int J Antimicrob Agents 2011;37(5):420-4
87. Yoshida K, Nakayama K, Ohtsuka M, et al. MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate. Bioorg Med Chem 2007;15(22):7087-97 (Pubitemid 47451787)
88. Lomovskaya O, Bostian KA. Practical applications and feasibility of efflux pump inhibitors in the clinic-a vision for applied use. Biochem Pharmacol 2006;71(7):910-18
89. Zeng B, Wang H, Zou L, et al. Evaluation and target validation of indole derivatives as inhibitors of the AcrAB-TolC efflux pump. Biosci Biotechnol Biochem 2010;74(11):2237-41
90. Mahamoud A, Chevalier J, Baitiche M, et al. An alkylaminoquinazoline restores antibiotic activity in Gram-negative resistant isolates. Microbiology 2011;157(Pt 2):566-71
91. Coban AY, Guney AK, Tanriverdi Cayci Y, Durupinar B. Effect of 1-(1-Naphtylmethyl)-piperazine, an efflux pump inhibitor, on antimicrobial drug susceptibilities of clinical Acinetobacter baumannii isolates. Curr Microbiol 2011;62(2):508-11
92. Liu YS, Zhang YQ, Yang LX, et al. Gene-specific silencing induced by parallel complementary RNA in Pseudomonas aeruginosa. Biotechnol Lett 2009;31(10):1571-5
93. Meng J, Bai H, Jia M, et al. Restoration of antibiotic susceptibility in fluoroquinolone-resistant Escherichia coli by targeting acrB with antisense phosphorothioate oligonucleotide encapsulated in novel anion liposome. J Antibiot (Tokyo) 2011;65:129-34
94. Al-Hamad A, Burnie J, Upton M. Enhancement of antibiotic susceptibility of Stenotrophomonas maltophilia using polyclonal antibody developed against an ABC multidrug efflux pump. Can J Microbiol 2011;57(10):820-8
95. Takatsuka Y, Chen C, Nikaido H. Mechanism of recognition of compounds of diverse structures by the multidrug efflux pump AcrB of Escherichia coli. Proc Natl Acad Sci USA 2010;107(15):6559-65
96. Lomovskaya O, Lee A, Hoshino K, et al. Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1999;43(6):1340-6 (Pubitemid 29259322)
97. (Pubitemid 44527526)
98. Robertson GT, Doyle TB, Du Q, et al. A Novel indole compound that inhibits Pseudomonas aeruginosa growth by targeting MreB is a substrate for MexAB-OprM. J Bacteriol 2007;189(19):6870-81 (Pubitemid 47525431)
99. Chuanchuen R, Karkhoff-Schweizer RR, Schweizer HP. High-level triclosan resistance in Pseudomonas aeruginosa is solely due to efflux. Am J Infect Control 2003;31(2):124-7 (Pubitemid 36432870)
100. Schweizer HP. When it comes to drug discovery not all Gram-negative bacterial biodefense pathogens are created equal: Burkholderia pseudomallei is different. Microb Biotechnol 2012; [Epub ahead of print]